ABCC1 p.Ser1034Cys
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 19307369
[PubMed]
Parquet V et al: "Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria."
No.
Sentence
Comment
99
The following mutations were identified in at least one strain: Pfcrt M74I, N75E, K76T, A220S, Q271(E/V), N326S, I356T, and I371R; Pfmrp H191Y and S437A; and Pfmdr1 N86Y, Y184F, S1034C, N1042D, and D1246Y (Table 2).
X
ABCC1 p.Ser1034Cys 19307369:99:178
status: NEW
PMID: 10704942
[PubMed]
Abrahem A et al: "Pleiotropic resistance to diverse antimalarials in actinomycin D-resistant Plasmodium falciparum."
No.
Sentence
Comment
185
Although these results point to the lack of involvement of Pfmdr1 in actD resistance, earlier reports have suggested that several point mutations in Pfmdr1 (Asn86Tyr, Ser1034Cys, Asn1042Asp, and Asp1246Tyr) may be important to chloroquine or mefloquine resistance [38].
X
ABCC1 p.Ser1034Cys 10704942:185:167
status: NEW
PMID: 8790436
[PubMed]
Ruetz S et al: "The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells."
No.
Sentence
Comment
38
Mutant variants ofpftndrl bearing a single Ser -> Cys substitution at position 1034 (S1034C, clone M1034), a single Asn -> Asp substitution at position 1042 (N1042D, clone M1042), or both mutations (S1034C/N1042D; clone DM) were generated by site-directed mutagenesis (26).
X
ABCC1 p.Ser1034Cys 8790436:38:85
status: NEWX
ABCC1 p.Ser1034Cys 8790436:38:199
status: NEW88 The expression of the wild-type P. falciparum Pgh-1 protein (A) and mutant variants bearing single S1034C (B) or N1042D (C) mutations or both (D) in permeabilized yeast S. cerevisiae spheroplasts is shown by immunofluorescence using a specific antiserum (rabbit anti-Pgh-1) at a 1:100 dilution, followed by an fluorescein isothiocyanate-coupled goat anti-rabbit antibody at a dilution of 1:800.
X
ABCC1 p.Ser1034Cys 8790436:88:99
status: NEW94 Time-dependent cell growth in absence (solid symbols) or presence (open symbols) of MFQ at 150 ,ug/ml was established for JPY201 transformants expressing wild-type Pgh-1, wild-type Mdr3 (Mdr3S), or Pgh-1 variants bearing single S1034C (M1034) or single N1042D (M1042) mutations or both mutations (S1034C/N1042D; DM) in predicted TM11 or a mutant variant of Mdr3 (S939F; Mdr3F).
X
ABCC1 p.Ser1034Cys 8790436:94:228
status: NEWX
ABCC1 p.Ser1034Cys 8790436:94:297
status: NEW97 JPY201 cells expressing wild-type Pgh-1, wild-type Mdr3 (Mdr3S), or mutant Pgh-1 variants bearing single S1034C (M1034), single N1042D M1042) mutations, or both mutations (S1034C/N1042D; DM) were evaluated for growth in increasing concentrations of MFQ.
X
ABCC1 p.Ser1034Cys 8790436:97:105
status: NEWX
ABCC1 p.Ser1034Cys 8790436:97:172
status: NEW133 JPY201 cells expressing either wild-type Pgh-1 or a double mutant Pgh-1 variant (S1034C/ N1042D; DM) were incubated with QA.
X
ABCC1 p.Ser1034Cys 8790436:133:81
status: NEW